42 completed, 9 active not recruiting, 7 recruiting, 7 terminated. 19 Phase 2, 4 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 11, Terminated 7, Active not recruiting 1 |
| Phase 3 | 4 | Recruiting 3, Active not recruiting 1 |
| Phase 1 | 2 | Completed 2 |
Follow Hellenic Cooperative Oncology Group: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Folate Receptor Alpha (FRα) Expression and Heterogeneity in Epithelial Ovarian Cancer High Grade Serous Ovarian Cancer, Folate Receptor Alpha Positive | Recruiting | Hellenic Cooperative Oncology Group | 200 | 2026-07-10 | 2026-10-22 | |
| Hellenic Evaluation of the Long-Term Safety and Efficacy of NalIriFOx as a 1st-line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Recruiting | Hellenic Cooperative Oncology Group | 70 | 2026-03-30 | 2026-07-24 | |
| Mechanisms of Response and Resistance to Innovative Treatments in Patients With Locally Advanced or Metastatic Breast Cancer Metastatic Breast Cancer | Recruiting | Hellenic Cooperative Oncology Group | 150 | 2024-10-15 | 2026-10-14 | |
| Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients CDK 4/6 inhibitors, Endocrine therapy - Metastatic Breast Cancer, Advanced Breast Cancer | Phase 3 | Recruiting | Region Örebro County | 495 | 2024-04-01 | 2024-11-19 |
| Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies Triple Negative Breast Cancer | Enrolling by invitation | Institute of Applied Biosciences | 150 | 2024-03-01 | 2024-10-17 | |
| PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer Standard treatment: Control arm, Experimental arm - Cervical Carcinoma, Adenocarcinoma | Phase 3 | Recruiting | Institut Claudius Regaud | 510 | 2023-12-20 | 2026-10-13 |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) Elacestrant, Tamoxifen, Letrozole 2.5mg - ER-positive Breast Cancer, HER2-negative Breast Cancer | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 220 | 2023-12-15 | 2026-10-07 |
| Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma Selinexor, Matching Placebo for selinexor - Endometrial Cancer | Phase 3 | Active not recruiting | Karyopharm Therapeutics Inc | 257 | 2023-04-18 | 2026-09-30 |
| Elements of Adaptive Immunity in Epithelial Ovarian Cancer Assessment of elements of adaptive immunity in tumor biopsies - Epithelial High Grade Serous Ovarian Cancer | Completed | Hellenic Cooperative Oncology Group | 687 | 2023-04-01 | 2026-07-27 | |
| Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan Antibody-Drug Conjugates - Breast Cancer, Metastatic Cancer | Completed | Hellenic Cooperative Oncology Group | 312 | 2023-01-01 | 2025-09-15 | |
| Clinical and Molecular Study With Digital Support of Patients With Inoperable Lung Cancer Digital platform - Non-Small Cell Carcinoma of Lung, TNM Stage 4 | Completed | Hellenic Cooperative Oncology Group | 200 | 2022-03-23 | 2026-06-24 | |
| Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer Olaparib + durvalumab + UV1 - Ovarian Cancer | Phase 2 | Active not recruiting | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | 188 | 2021-12-15 | 2026-02-27 |
| Real-world Data in Patients With Breast Cancer Treated With Abemaciclib Breast Cancer | Recruiting | Hellenic Cooperative Oncology Group | 108 | 2021-10-06 | 2026-07-21 | |
| Head and Neck cancERs International cOviD-19 collabOraTion non interventional study - Head and Neck Cancer, Covid19 | Unknown | Hellenic Cooperative Oncology Group | 750 | 2021-05-03 | 2022-03-17 | |
| Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer | Active not recruiting | Hellenic Cooperative Oncology Group | 50 | 2021-03-31 | 2026-10-15 | |
| Responses to COVID-19 Vaccination in Patients With Cancer IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus - Cancer | Completed | Hellenic Cooperative Oncology Group | 332 | 2021-01-12 | 2022-08-17 | |
| Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune Disease Checkpoint inhibitor - Autoimmune Diseases, Checkpoint Inhibitor | Completed | Hellenic Cooperative Oncology Group | 126 | 2020-11-01 | 2021-03-22 | |
| Molecular Profiling in Prostate Cancer Tumor molecular profiling - Prostate Cancer Metastatic, Prostate Cancer Recurrent | Completed | Hellenic Cooperative Oncology Group | 250 | 2020-10-01 | 2026-10-16 | |
| Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer Lung Cancer Non-small Cell Stage IV | Active not recruiting | Hellenic Cooperative Oncology Group | 40 | 2020-02-01 | 2026-10-16 | |
| Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer PARP inhibitor - Ovarian Cancer | Completed | Hellenic Cooperative Oncology Group | 180 | 2019-11-01 | 2026-10-19 |
Showing 20 of 68. Sign in to see all of them.
Breast Neoplasms (20) · Carcinoma, Non-Small-Cell Lung (8) · Ovarian Neoplasms (5) · Colorectal Neoplasms (3) · Prostatic Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Brain Neoplasms (2) · Head and Neck Neoplasms (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Small Cell Lung Carcinoma (2) · Stomach Neoplasms (2) · Adenocarcinoma (1) · Amyloidosis (1) · Autoimmune Diseases (1)
High-Throughput Nucleotide Sequencing (2) · Panitumumab (2) · Ramucirumab (2) · cabazitaxel (2) · durvalumab (2) · olaparib (2) · temsirolimus (2) · Afatinib (1) · Aging (1) · Anastrozole (1) · Bevacizumab (1) · Blood Specimen Collection (1) · Cisplatin (1) · Cyclophosphamide (1) · Dexamethasone (1)
Greece (55) · Italy (5) · Spain (5) · Belgium (3) · Ireland (3) · Sweden (3) · Cyprus (2) · Czechia (2) · France (2) · Germany (2) · Netherlands (2) · Portugal (2) · Switzerland (2) · United States (2) · Australia (1)
Evangelos Briasoulis, MD (2) · George Papaxoinis, MD (2) · Helena Linardou, MD (2) · Joseph Sgouros, MD (2) · Adamantia Nikolaidi (1) · Adamantia Nikolaidi, MD (1) · Angelos Koutras, MD (1) · Anna Koumarianou, Dr (1) · Antonios Valachis, Assoc Prof (1) · Aristotelis Bamias, MD, PhD (1) · Athina Christopoulou, MD, PhD (1) · Christos Christodoulou, MD (1) · Diamanto Psyrri, MD,Ass.Prof (1) · Dimitrios Pectasides, Professor (1)
PMID 16148021, PMID 17303906, PMID 18568771, PMID 22187126, PMID 22517904, PMID 23718900, PMID 23935969, PMID 24004667, PMID 25026897, PMID 26291008, PMID 27872060, PMID 29855806, PMID 30374686, PMID 32182791, PMID 32731409, PMID 32817060, PMID 33397968, PMID 33429865, PMID 33714009, PMID 34003074, PMID 34141624, PMID 34164709, PMID 34512058, PMID 36428728, PMID 38176305, PMID 38572764, PMID 38613914, PMID 38627035, PMID 38834399, PMID 39431459, PMID 40805239, PMID 40966692, PMID 41632937
2009 (2), 2017 (2), 2008 (1), 2014 (1), 2015 (1), 2016 (1)